Sector Alpha Week of 2026-08-07
Sector Alpha — machine-written from the numbers · Data as of 2026-08-07

Danlaw Technologies India Ltd

532329
IT - Software

Danlaw Technologies India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

The sharpest disagreement: profits are rising, but only 29% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.

The price is in a confirmed uptrend (8 weeks in) while the P/E sits at the 79th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit −30.7% year on year, and 29% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.

Price
₹1,198
P/E
115.0×
79th pctile
of its own 10-year range
Revenue (Sep 22)
₹38.0 Cr
+24.5% YoY
Profit (Sep 22)
₹1.2 Cr
−30.7% YoY
Operating margin
8.9%
+1.0 pp YoY
ROCE
8%
FY22
Cash conversion
29%
of profit, last 3 FY
Unverified figures: Some figures on this page come from a second financial-data feed that could not be cross-checked against the primary source — the two do not share enough overlapping reported history to compare. They are drawn, because they are the only evidence there is, and every section carrying one is marked unverified.
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Danlaw Technologies India Ltd trades at ₹1,198, in a confirmed uptrend and 8 weeks into that stage. That is +36.5% against its own 200-day average. It sits at 100% of a 52-week range of ₹746 to ₹1,198. On relative strength it has no relative-strength read yet.

Today the stock is in a confirmed uptrend — week 8 of stage 2, confirmed. At ₹1,198 it trades +36.5% versus its 200-day average and sits at 100% of its 52-week range (₹746–₹1,198).

Aug 26: ₹1,198 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
+36.5% versus the 200-day line, week 8 of stage 2
Price50-day avg200-day avg
S4S2₹1,237₹1,096₹955₹814₹673₹1,198₹878May 26Jun 26Jun 26Jul 26Aug 26
S4S2₹1,237₹1,096₹955₹814₹673₹1,198₹878May 26Jun 26Aug 26

Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +61% while the NIFTY 500 moved +5% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Danlaw Technologies India Ltd trades at 115.0× P/E, at the pricey end of its own range (79th percentile). Its long-run median P/E is 56.8×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 115.0× is at the pricey end of its own range (79th percentile), against a long-run median of 56.8× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 115.0× vs a 56.8× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 10.1-year window; loss-period spikes above 170× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
at the pricey end of its own range (79th percentile)
P/EMedianEPS (TTM) (quarterly)
183.1×₹15.7137.3×₹11.891.6×₹7.945.8×₹3.90.0×₹0.0×87.50×₹14Jul 16Nov 21Jun 23Jan 25Aug 26
183.1×₹15.7137.3×₹11.891.6×₹7.945.8×₹3.90.0×₹0.0×87.50×₹14Jul 16Jun 23Aug 26
P/E
115.0×
79th percentile of 10y

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Danlaw Technologies India Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 9 quarters across 2 curves, on partial evidence.

Growth, year by year: revenue +23.2% in FY22, profit +100.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn. Turnaround-year spikes shown pinned (▲).
Revenue YoYProfit YoYEPS YoY
190%340%135%195%80%50%25%−95%−31%−240%%%23.2%100%FY12FY17FY22
190%340%135%195%80%50%25%−95%−31%−240%%%23.2%100%FY12FY17FY22
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Where the trailing-twelve-month history is short, the curve falls back to single-quarter year-on-year growth — noisier, and the classifier smooths and caps base-effect spikes before reading. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over
RevenueProfitEPS
239%323%170%240%101%157%32%74%−37%−8.9%%%24.5%14%126.8%Dec 19Mar 21Sep 22
239%323%170%240%101%157%32%74%−37%−8.9%%%24.5%14%126.8%Dec 19Mar 21Sep 22
ROCE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROCE
13%4.5%−4.5%−13%−22%%8%FY19FY20FY22
13%4.5%−4.5%−13%−22%%8%FY19FY20FY22
Revenue growth
Rising
latest +24.5% · span −18.4% to +100.0%
ROCE
Stuck low
latest 8.0% · span −20.0%–11.0%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+23.2%+30.4%+56.5%+29.8%
Profit+100.0%
EPS+1,216.7%+24.5%
Revenue YoY (Sep 22)
+24.5%
latest quarter vs a year ago
Profit YoY (Sep 22)
−30.7%
latest quarter vs a year ago
Revenue 10y
29.8%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

44.9/100 — rank 60 of 64 in IT - Software · 32% evidence confidence · provisional, ranked below fully-evidenced peers

Danlaw Technologies India Ltd scores 44.9 out of 100 against the 64 companies it is compared with in IT - Software, ranking 60. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 16.3 + 7.7 + 8.7 + 12.2 = 44.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Danlaw Technologies India Ltd reported ₹38.0 Cr of revenue in the Sep 22 quarter, +24.5% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 29.8% a year. The last full year, FY22, came in at ₹122 Cr. The last four reported quarters add to ₹138 Cr.

FY22 revenue came in at ₹122 Cr (+23.2% on the year), capping 10 years at 29.8% compound. The latest quarter (Sep 22) printed ₹38.0 Cr, +24.5% year on year — the 3rd consecutive quarter of year-over-year growth.

FY22 revenue ₹122 Cr (+23.2% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
29.8% a year over 10 years
RevenueYoY growth
132190%99135%6680%3325%0−31%₹ Cr%₹12223.2%FY12FY17FY22
132190%99135%6680%3325%0−31%₹ Cr%₹12223.2%FY12FY17FY22
Sep 22: ₹38.0 Cr (+24.5% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
3rd straight quarter of growth
Revenue (quarterly)YoY growth
41239%31170%21101%1032%0−37%₹ Cr%₹3824.5%Dec 19Mar 21Sep 22
41239%31170%21101%1032%0−37%₹ Cr%₹3824.5%Dec 19Mar 21Sep 22

Pace check: the last four quarters averaged +12.4% growth against the decade's 29.8% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +10.9% over the last 4 quarters against +49.7%/yr over the last 8 — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Danlaw Technologies India Ltd's operating margin is 8.9% in the Sep 22 quarter, +1.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −8.0% to 18.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 8.9%, +1.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −8.0%–18.0%.

Why the margin moved: operating margin went +1.0 pp year on year while gross margin went −1.8 pp — the gain came mostly from the gross line: input costs and pricing.

FY22: 5.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 12-year window.
within a −8.0–18.0% band over 12 years
operating marginYoY change (pp)
20%24%13%15%5.0%6.2%−2.5%−2.7%−10%−12%%%5%−1%FY11FY16FY22
20%24%13%15%5.0%6.2%−2.5%−2.7%−10%−12%%%5%−1%FY11FY16FY22
Sep 22: 8.9% operating margin (+1.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
15%47%2.9%32%−9.6%17%−22%2.4%−34%−13%%%8.9%1%Dec 19Mar 21Sep 22
15%47%2.9%32%−9.6%17%−22%2.4%−34%−13%%%8.9%1%Dec 19Mar 21Sep 22
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Danlaw Technologies India Ltd earned ₹1.2 Cr of net profit in the Sep 22 quarter, −30.7% year on year. Full-year FY22 profit was ₹4.0 Cr. That is 3.3% of the quarter's revenue. The same quarter a year earlier earned ₹1.8 Cr. 6 of the last 12 reported quarters were loss-making.

Sep 22 profit was ₹1.2 Cr, −30.7% year on year. On the full year, FY22 printed ₹4.0 Cr (+100.0%).

FY22 profit ₹4.0 Cr (+100.0% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
5124%237%−1−50%−3−137%−6−224%₹ Cr%₹4100%FY12FY17FY22
5124%237%−1−50%−3−137%−6−224%₹ Cr%₹4100%FY12FY17FY22
Sep 22: ₹1.2 Cr (−30.7% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
4164%285%05.4%−1−74%−3−153%₹ Cr%₹1−30.7%Dec 19Mar 21Sep 22
4164%285%05.4%−1−74%−3−153%₹ Cr%₹1−30.7%Dec 19Mar 21Sep 22
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 29% of Danlaw Technologies India Ltd's reported profit arrived as operating cash — a gap worth watching. In FY22 that was ₹6.0 Cr of operating cash against ₹4.0 Cr of profit. After ₹5.0 Cr of capital spending, ₹1.0 Cr was left as free cash.

FY22: operating cash of ₹6.0 Cr against reported profit of ₹4.0 Cr, leaving free cash of ₹1.0 Cr after ₹5.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 29% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY22: CFO ₹6.0 Cr vs profit ₹4.0 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 11-year window, annual resolution. FY21 reflects an acquisition year — point shown clipped.
29% of 3-year profit arrived as cash
Operating cashNet profitFree cash
1483−3−9₹ Cr₹6₹4₹1FY12FY17FY22
1483−3−9₹ Cr₹6₹4₹1FY12FY17FY22
FY22: CFO = 150% of profit (three-year rate 29%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash.
Conversion100%
248%74%−100%−274%−448%%150%FY12FY17FY22
248%74%−100%−274%−448%%150%FY12FY17FY22

🚨 Why conversion sits at 29%: the cash cycle tightened 115 days between FY17 and FY22 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: the bigger cash user is investment — capital spending ran 2.6× depreciation over three years, so the next section's job is to check what that build-out is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Danlaw Technologies India Ltd's cash conversion cycle runs 105 days in FY22, down from 220 days in FY17. Capital spending ran ₹29.0 Cr over the last 3 years. At FY22 sales of ₹122 Cr each day of that cycle holds about ₹0.3 Cr, so roughly ₹35.0 Cr sits inside the business at any moment.

FY22: debtors at 55 days, inventory at 130 days — roughly 4.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 105 days, tighter than FY17's 220.

The full loop: cash goes out to suppliers and production on day 0; stock waits 130 days to sell; customers pay about 55 days after that; and suppliers themselves are paid at 80 days — netting out to the 105-day cycle.

In money terms: at FY22 sales of ₹122 Cr, each day of the cycle holds about ₹0.3 Cr — so the 105-day loop keeps roughly ₹35.0 Cr sitting inside the business at any moment.

FY22: a 105-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 12-year window.
−115 days vs FY17
Cash cycleInventory daysDebtor daysPayable days
331248164800days105d130d55d80dFY11FY13FY16FY19FY22
331248164800days105d130d55d80dFY11FY16FY22

On the investment side: capital spending of ₹29.0 Cr over the last 3 fiscal years against ₹11.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY22) — capacity paid for but not yet earning.

FY22: capex ₹5.0 Cr, work-in-progress ₹0.0 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
a build-out
CapexWork-in-progress
161272−2₹ Cr₹5₹0FY12FY14FY17FY19FY22
161272−2₹ Cr₹5₹0FY12FY17FY22

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Danlaw Technologies India Ltd earns a ROCE of 8% in FY22. That is up from a trough of −20% in FY20. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 3.3% net margin on 1.37× asset turns.

FY22 ROCE is 8%, recovered from a FY20 trough of −20% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY22): 3.3% net margin × 1.37× asset turns × 3.87× balance-sheet leverage ≈ 17.5% on equity. Margin does its share; leverage is a meaningful part of the equation.

FY22: ROCE 8% Return on capital employed by fiscal year, % (line). 12-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the climb back from FY20's −20%
ROCEWACC
19%8.4%−2.0%−12%−23%%8%FY11FY13FY16FY19FY22
19%8.4%−2.0%−12%−23%%8%FY11FY16FY22
11 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Danlaw Technologies India Ltd carries ₹12.0 Cr of borrowings against ₹23.0 Cr of equity in FY22, a debt-to-equity of 0.52. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹0.0 Cr to ₹12.0 Cr. Capital spending ran ₹29.0 Cr across the last 3 of those years.

FY22: borrowings of ₹12.0 Cr against equity of ₹23.0 Cr — a debt-to-equity of 0.52. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹0.0 Cr to ₹12.0 Cr while capital spending ran ₹29.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.

FY22: borrowings ₹12.0 Cr at 0.52× equity Borrowings by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 12-year window. Quarterly balance-sheet history is not held for India — annual is the honest resolution.
the debt trajectory
BorrowingsDebt-to-equity
130.6×100.4×60.3×30.1×00.0×₹ Cr×₹120.52×FY11FY13FY16FY19FY22
130.6×100.4×60.3×30.1×00.0×₹ Cr×₹120.52×FY11FY16FY22
12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Danlaw Technologies India Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved +0.0 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +0.0 points over 8 quarters to 61.9%; Foreign institutions: +0.0 points over 8 quarters to 0.0%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.

Fiscal-year ends: promoters +0.0 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersForeign inst.Domestic inst.Public
67%49%31%13%−4.9%%61.9%0%0%37.2%Mar 24Mar 25Mar 26
67%49%31%13%−4.9%%61.9%0%0%37.2%Mar 24Mar 25Mar 26
A quiet register: no holder moved a full point in two years Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersForeign inst.Domestic inst.Public
67%49%31%13%−4.9%%61.9%0%0.0%37.2%Jun 23Dec 24Jun 26
67%49%31%13%−4.9%%61.9%0%0.0%37.2%Jun 23Dec 24Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Danlaw Technologies India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

14 · Related companies · IT - Software
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Coforge LtdCOFORGE 76.1/100Favorable setup100% evidence BREAKING OUT 30.2/35 Revenue 35.7% · PAT 66.5% · OPM change 3 pp 100% evidence 15.7/25 ROCE 23.5% · OPM 19% 100% evidence 12.7/20 P/E 41× · PEG 0.57 100% evidence 17.5/20 RS sector 8.3% · RS bench 12.6% · 1Y 4.1%12 of 12 weeks ahead 100% evidence
Exact sum: 30.2 + 15.7 + 12.7 + 17.5 = 76.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Silver Touch Technologies LtdSILVERTUC 71.8/100Favorable setup93% evidence LEADER 30.5/35 Revenue 21.1% · PAT 86.4% · OPM change 8 pp 100% evidence 17.4/25 ROCE 29.8% · OPM 22% 100% evidence 10.2/20 P/E 59.6× · PEG 1.11 65% evidence 13.7/20 RS sector 44% · RS bench 52.8% · 1Y 163.6%12 of 12 weeks ahead 100% evidence
Exact sum: 30.5 + 17.4 + 10.2 + 13.7 = 71.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
3NINtec Systems LtdNINSYS 68.0/100Favorable setup76% evidence LEADER 20.8/35 Revenue 21.7% · PAT 21.6% · OPM change 8.1 pp 83% evidence 22.0/25 ROCE 55% · OPM 30.1% 95% evidence 9.2/20 P/E 42.9× · PEG — 15% evidence 16.0/20 RS sector 37.4% · RS bench 43.6% · 1Y 71.6%12 of 12 weeks ahead 100% evidence
Exact sum: 20.8 + 22 + 9.2 + 16 = 68 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4ASM Technologies Ltd526433 68.0/100Favorable setup69% evidence TURNING 28.1/35 Revenue 67.8% · PAT 89.5% · OPM change 2 pp 95% evidence 16.3/25 ROCE 27% · OPM 23% 76% evidence 8.8/20 P/E 96.5× · PEG — 15% evidence 14.8/20 RS sector 5.7% · RS bench 39.5% · 1Y 78.7%10 of 10 weeks ahead 70% evidence
Exact sum: 28.1 + 16.3 + 8.8 + 14.8 = 68 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
5Sasken Technologies LtdSASKEN 66.9/100Favorable setup100% evidence LEADER 30.9/35 Revenue 67.8% · PAT 67.4% · OPM change 4 pp 100% evidence 8.0/25 ROCE 9.9% · OPM 9% 100% evidence 9.6/20 P/E 39.6× · PEG 0.68 100% evidence 18.4/20 RS sector 18.7% · RS bench 24.2% · 1Y 31.7%12 of 12 weeks ahead 100% evidence
Exact sum: 30.9 + 8 + 9.6 + 18.4 = 66.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6InfoBeans Technologies LtdINFOBEAN 66.9/100Favorable setup81% evidence ASLEEP 26.8/35 Revenue 35.5% · PAT 60.4% · OPM change 0 pp 95% evidence 16.8/25 ROCE 29.2% · OPM 21% 95% evidence 9.5/20 P/E 19.2× · PEG — 50% evidence 13.8/20 RS sector 17.4% · RS bench -1.4% · 1Y 22.3%4 of 10 weeks ahead 70% evidence
Exact sum: 26.8 + 16.8 + 9.5 + 13.8 = 66.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
7Sahana Systems LtdSAHANA 64.7/100Mixed-positive evidence70% evidence BASING 21.7/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence 19.6/25 ROCE 39.8% · OPM 29% 95% evidence 14.5/20 P/E 12.7× · PEG — 50% evidence 8.9/20 RS sector -19% · RS bench -1.3% · 1Y -34.6%0 of 12 weeks ahead 100% evidence
Exact sum: 21.7 + 19.6 + 14.5 + 8.9 = 64.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Tech Mahindra LtdTECHM 63.5/100Mixed-positive evidence94% evidence TURNING 21.2/35 Revenue 10.9% · PAT 14.3% · OPM change 3 pp 100% evidence 16.3/25 ROCE 23.1% · OPM 17% 100% evidence 10.9/20 P/E 30.1× · PEG 0.76 100% evidence 15.1/20 RS sector 14.8% · RS bench 6.9% · 1Y 13.6%5 of 11 weeks ahead 70% evidence
Exact sum: 21.2 + 16.3 + 10.9 + 15.1 = 63.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Datamatics Global Services LtdDATAMATICS 63.1/100Mixed-positive evidence94% evidence TURNING 21.3/35 Revenue 13.1% · PAT 1.9% · OPM change 4 pp 100% evidence 16.1/25 ROCE 20.8% · OPM 20% 100% evidence 11.3/20 P/E 20.2× · PEG 0.58 100% evidence 14.4/20 RS sector 9.6% · RS bench 3.9% · 1Y -13.9%6 of 10 weeks ahead 70% evidence
Exact sum: 21.3 + 16.1 + 11.3 + 14.4 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Hypersoft Technologies Ltd539724 63.1/100Mixed-positive evidence61% evidence LEADER 25.6/35 Revenue 100% · PAT 100% · OPM change 2.9 pp 71% evidence 12.0/25 ROCE 20.6% · OPM 14% 76% evidence 8.6/20 P/E 421× · PEG — 15% evidence 16.9/20 RS sector 65% · RS bench 74.2% · 1Y 230.2%12 of 12 weeks ahead 70% evidence
Exact sum: 25.6 + 12 + 8.6 + 16.9 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Cigniti Technologies LtdCIGNITITEC 62.6/100Mixed-positive evidence79% evidence 23.5/35 Revenue 14% · PAT 96.1% · OPM change 2 pp 56% evidence 16.2/25 ROCE 34.1% · OPM 18% 75% evidence 16.0/20 P/E 11.4× · PEG 0.61 100% evidence 6.9/20 RS sector -9.5% · RS bench -15% · 1Y -21.7%0 of 12 weeks ahead to 2026-05-17 100% evidence
Exact sum: 23.5 + 16.2 + 16 + 6.9 = 62.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.5% and the one-year return is -21.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
12Softtech Engineers LtdSOFTTECH 60.9/100Mixed-positive evidence76% evidence FADING 27.9/35 Revenue 39.5% · PAT 100% · OPM change 6.2 pp 83% evidence 11.7/25 ROCE 6.2% · OPM 21.4% 95% evidence 8.7/20 P/E 118× · PEG — 15% evidence 12.6/20 RS sector 10.5% · RS bench 15.3% · 1Y 15.6%10 of 12 weeks ahead 100% evidence
Exact sum: 27.9 + 11.7 + 8.7 + 12.6 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13BLS E-Services LtdBLSE 58.6/100Mixed-positive evidence75% evidence LEADER 19.2/35 Revenue 71.2% · PAT 9.4% · OPM change 0 pp 95% evidence 10.7/25 ROCE 17% · OPM 7% 76% evidence 9.0/20 P/E 48.6× · PEG — 15% evidence 19.7/20 RS sector 47% · RS bench 53.4% · 1Y 69.5%12 of 12 weeks ahead 100% evidence
Exact sum: 19.2 + 10.7 + 9 + 19.7 = 58.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14String Metaverse Ltd534535 58.0/100Mixed-positive evidence78% evidence BASING 26.2/35 Revenue 100% · PAT 100% · OPM change 0 pp 83% evidence 15.4/25 ROCE 41.6% · OPM 10% 76% evidence 14.7/20 P/E 8.2× · PEG — 50% evidence 1.7/20 RS sector -60.9% · RS bench -52.1% · 1Y -75.3%0 of 12 weeks ahead 100% evidence
Exact sum: 26.2 + 15.4 + 14.7 + 1.7 = 58 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -60.9% and the one-year return is -75.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
15TAC Infosec LtdTAC 57.9/100Thin evidence · provisional54% evidence TURNING 21.5/35 Revenue — · PAT — · OPM change 1.6 pp 39% evidence 20.6/25 ROCE 38.1% · OPM 48.2% 95% evidence 9.5/20 P/E 39× · PEG — 15% evidence 6.3/20 RS sector -13.2% · RS bench -12% · 1Y 18.8%1 of 10 weeks ahead 70% evidence
Exact sum: 21.5 + 20.6 + 9.5 + 6.3 = 57.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Ksolves India LtdKSOLVES 57.2/100Mixed-positive evidence87% evidence ASLEEP 17.9/35 Revenue 16% · PAT 16.7% · OPM change 3.9 pp 95% evidence 20.5/25 ROCE 131% · OPM 30.3% 95% evidence 13.6/20 P/E 17.9× · PEG — 50% evidence 5.2/20 RS sector -12.5% · RS bench -8.4% · 1Y -11.3%0 of 12 weeks ahead 100% evidence
Exact sum: 17.9 + 20.5 + 13.6 + 5.2 = 57.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Infosys LtdINFY 57.1/100Mixed-positive evidence82% evidence BASING 18.4/35 Revenue 11.2% · PAT 11.1% · OPM change 0 pp 95% evidence 20.1/25 ROCE 40% · OPM 24% 76% evidence 13.9/20 P/E 15.3× · PEG — 50% evidence 4.7/20 RS sector -19.8% · RS bench -16.1% · 1Y -20%0 of 12 weeks ahead 100% evidence
Exact sum: 18.4 + 20.1 + 13.9 + 4.7 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Subex LtdSUBEXLTD 56.7/100Mixed-positive evidence65% evidence TURNING 24.5/35 Revenue 2.8% · PAT 100% · OPM change 13 pp 95% evidence 10.4/25 ROCE 12.8% · OPM 19% 95% evidence 9.9/20 P/E 23.9× · PEG — 15% evidence 11.9/20 RS sector — · RS bench 19.3% · 1Y —4 of 4 weeks ahead 25% evidence
Exact sum: 24.5 + 10.4 + 9.9 + 11.9 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19R Systems International LtdRSYSTEMS 55.6/100Mixed-positive evidence100% evidence ASLEEP 19.3/35 Revenue 24.1% · PAT -1% · OPM change 3 pp 100% evidence 16.6/25 ROCE 19.5% · OPM 18% 100% evidence 18.2/20 P/E 13.9× · PEG 0.26 100% evidence 1.5/20 RS sector -31.2% · RS bench -28.6% · 1Y -41%0 of 12 weeks ahead 100% evidence
Exact sum: 19.3 + 16.6 + 18.2 + 1.5 = 55.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Xchanging Solutions LtdXCHANGING 55.2/100Mixed-positive evidence77% evidence ASLEEP 21.1/35 Revenue 9.7% · PAT 18% · OPM change 3 pp 83% evidence 15.4/25 ROCE 18% · OPM 37% 95% evidence 13.4/20 P/E 12.6× · PEG — 50% evidence 5.3/20 RS sector -24.4% · RS bench -10.8% · 1Y -23.2%1 of 10 weeks ahead 70% evidence
Exact sum: 21.1 + 15.4 + 13.4 + 5.3 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21RNIT AI Solutions LtdAUTOPALIND 54.4/100Thin evidence · provisional51% evidence 20.5/35 Revenue 59.8% · PAT 66.7% · OPM change 5.1 pp 83% evidence 14.6/25 ROCE 20.2% · OPM 40.2% 76% evidence 9.3/20 P/E 39.8× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —4 of 9 weeks ahead 0% evidence
Exact sum: 20.5 + 14.6 + 9.3 + 10 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22LTM LtdLTM 54.2/100Mixed-positive evidence100% evidence TURNING 17.4/35 Revenue 13.9% · PAT 10% · OPM change 1 pp 100% evidence 17.8/25 ROCE 29.6% · OPM 18% 100% evidence 11.2/20 P/E 24.6× · PEG 1.18 100% evidence 7.8/20 RS sector -12.4% · RS bench -8.5% · 1Y -7.2%0 of 12 weeks ahead 100% evidence
Exact sum: 17.4 + 17.8 + 11.2 + 7.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23AvenuesAI LtdCCAVENUE 54.2/100Mixed-positive evidence83% evidence BREAKING OUT 20.3/35 Revenue 100% · PAT 25.5% · OPM change -2.3 pp 88% evidence 8.3/25 ROCE 7.7% · OPM 3.7% 100% evidence 14.8/20 P/E 21.3× · PEG 0.37 65% evidence 10.8/20 RS sector -2.2% · RS bench 3.2% · 1Y 11.6%6 of 11 weeks ahead 70% evidence
Exact sum: 20.3 + 8.3 + 14.8 + 10.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Tanla Platforms LtdTANLA 53.7/100Mixed-positive evidence94% evidence TURNING 14.7/35 Revenue 13.2% · PAT 9.9% · OPM change 0 pp 100% evidence 16.6/25 ROCE 26.3% · OPM 16% 100% evidence 12.9/20 P/E 15.3× · PEG 1.21 100% evidence 9.5/20 RS sector -12% · RS bench 8.9% · 1Y -0.5%9 of 10 weeks ahead 70% evidence
Exact sum: 14.7 + 16.6 + 12.9 + 9.5 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25HCL Technologies LtdHCLTECH 53.7/100Mixed-positive evidence76% evidence TURNING 12.7/35 Revenue 12.6% · PAT 2.6% · OPM change 0 pp 95% evidence 19.1/25 ROCE 30.4% · OPM 20% 76% evidence 9.5/20 P/E 20.3× · PEG — 50% evidence 12.4/20 RS sector 9.9% · RS bench -6.5% · 1Y -6.6%2 of 10 weeks ahead 70% evidence
Exact sum: 12.7 + 19.1 + 9.5 + 12.4 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Saksoft LtdSAKSOFT 53.3/100Mixed-positive evidence94% evidence BREAKING OUT 18.4/35 Revenue 8.2% · PAT 13% · OPM change 0 pp 100% evidence 15.7/25 ROCE 25.5% · OPM 18% 100% evidence 13.2/20 P/E 16.3× · PEG 0.6 100% evidence 6.0/20 RS sector -21.2% · RS bench -6.1% · 1Y -19.9%7 of 11 weeks ahead 70% evidence
Exact sum: 18.4 + 15.7 + 13.2 + 6 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27Seshaasai Technologies LtdSTYL 52.5/100Mixed-positive evidence73% evidence TURNING 13.0/35 Revenue 6.7% · PAT 20.6% · OPM change 0 pp 100% evidence 17.0/25 ROCE 27.7% · OPM 23% 100% evidence 12.5/20 P/E 25× · PEG 0.81 65% evidence 10.0/20 RS sector — · RS bench — · 1Y —9 of 10 weeks ahead 0% evidence
Exact sum: 13 + 17 + 12.5 + 10 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Tata Consultancy Services LtdTCS 52.4/100Mixed-positive evidence94% evidence ASLEEP 10.7/35 Revenue 7.7% · PAT 1.1% · OPM change -1 pp 100% evidence 22.4/25 ROCE 63% · OPM 26% 100% evidence 11.8/20 P/E 16.5× · PEG 1.85 100% evidence 7.5/20 RS sector -4.6% · RS bench -12.5% · 1Y -18.3%0 of 10 weeks ahead 70% evidence
Exact sum: 10.7 + 22.4 + 11.8 + 7.5 = 52.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
29Dynacons Systems & Solutions LtdDSSL 52.0/100Mixed-positive evidence83% evidence FADING 15.8/35 Revenue 12.4% · PAT 19.4% · OPM change 0 pp 83% evidence 16.9/25 ROCE 29.8% · OPM 9% 95% evidence 7.8/20 P/E 18.4× · PEG — 50% evidence 11.5/20 RS sector 6.8% · RS bench 12.2% · 1Y 23.6%11 of 12 weeks ahead 100% evidence
Exact sum: 15.8 + 16.9 + 7.8 + 11.5 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
30Expleo Solutions LtdEXPLEOSOL 51.4/100Mixed-positive evidence77% evidence ASLEEP 15.3/35 Revenue 8.1% · PAT 20.4% · OPM change -1 pp 83% evidence 15.9/25 ROCE 24.2% · OPM 15% 95% evidence 13.8/20 P/E 9.8× · PEG — 50% evidence 6.4/20 RS sector -13.4% · RS bench -9.8% · 1Y -28.2%4 of 10 weeks ahead 70% evidence
Exact sum: 15.3 + 15.9 + 13.8 + 6.4 = 51.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
31IZMO LtdIZMO 50.9/100Mixed-positive evidence77% evidence TURNING 15.9/35 Revenue 26.1% · PAT -2% · OPM change -5 pp 83% evidence 12.6/25 ROCE 12.6% · OPM 14% 95% evidence 6.6/20 P/E 31× · PEG — 50% evidence 15.8/20 RS sector 28.9% · RS bench 15.7% · 1Y 172.8%8 of 10 weeks ahead 70% evidence
Exact sum: 15.9 + 12.6 + 6.6 + 15.8 = 50.9 · Decision use: Price leads the evidence: RS versus the benchmark is 15.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
32Birlasoft LtdBSOFT 50.8/100Mixed-positive evidence100% evidence BASING 19.9/35 Revenue 1.4% · PAT 21.1% · OPM change 4 pp 100% evidence 13.1/25 ROCE 21.2% · OPM 16% 100% evidence 14.4/20 P/E 14.9× · PEG 0.62 100% evidence 3.4/20 RS sector -19.2% · RS bench -15.2% · 1Y -20.4%0 of 12 weeks ahead 100% evidence
Exact sum: 19.9 + 13.1 + 14.4 + 3.4 = 50.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
33Capillary Technologies India LtdCAPILLARY 50.5/100Mixed-positive evidence63% evidence ASLEEP 27.5/35 Revenue 27.8% · PAT 135.8% · OPM change 5.8 pp 100% evidence 4.1/25 ROCE 3.4% · OPM 15.7% 100% evidence 8.9/20 P/E 87.1× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence
Exact sum: 27.5 + 4.1 + 8.9 + 10 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
34Mastek LtdMASTEK 50.2/100Mixed-positive evidence82% evidence TURNING 14.2/35 Revenue 6% · PAT 5% · OPM change 0 pp 95% evidence 13.8/25 ROCE 18% · OPM 15% 76% evidence 12.7/20 P/E 13× · PEG — 50% evidence 9.5/20 RS sector -10.5% · RS bench -6.9% · 1Y -25.1%1 of 12 weeks ahead 100% evidence
Exact sum: 14.2 + 13.8 + 12.7 + 9.5 = 50.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
35Wipro LtdWIPRO 50.0/100Mixed-positive evidence94% evidence ASLEEP 13.4/35 Revenue 6.4% · PAT -1.7% · OPM change 0 pp 100% evidence 15.1/25 ROCE 17.8% · OPM 19% 100% evidence 13.1/20 P/E 14× · PEG 1.4 100% evidence 8.4/20 RS sector -1.9% · RS bench -17.2% · 1Y -22.7%0 of 10 weeks ahead 70% evidence
Exact sum: 13.4 + 15.1 + 13.1 + 8.4 = 50 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
36Blue Cloud Softech Solutions Ltd539607 49.3/100Mixed-negative evidence65% evidence ASLEEP 20.3/35 Revenue 25.7% · PAT 39.5% · OPM change 8 pp 83% evidence 10.9/25 ROCE 14.2% · OPM 17% 76% evidence 9.6/20 P/E 30.1× · PEG — 15% evidence 8.5/20 RS sector -1.9% · RS bench -14.2% · 1Y -41.8%0 of 10 weeks ahead 70% evidence
Exact sum: 20.3 + 10.9 + 9.6 + 8.5 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
37Mphasis LtdMPHASIS 48.8/100Mixed-negative evidence94% evidence TURNING 15.5/35 Revenue 13.7% · PAT 9.9% · OPM change -1 pp 100% evidence 17.4/25 ROCE 22.1% · OPM 18% 100% evidence 5.6/20 P/E 24.4× · PEG 2.19 100% evidence 10.3/20 RS sector 0% · RS bench -4.8% · 1Y -10.2%1 of 10 weeks ahead 70% evidence
Exact sum: 15.5 + 17.4 + 5.6 + 10.3 = 48.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
38TechNVision Ventures LtdTECHNVISN 48.3/100Mixed-negative evidence62% evidence ASLEEP 16.9/35 Revenue 18.2% · PAT 90.9% · OPM change -5.7 pp 62% evidence 8.9/25 ROCE 12.9% · OPM -4.1% 95% evidence 8.5/20 P/E 16333× · PEG — 15% evidence 14.0/20 RS sector 32.1% · RS bench -2% · 1Y 41.8%0 of 7 weeks ahead 70% evidence
Exact sum: 16.9 + 8.9 + 8.5 + 14 = 48.3 · Decision use: Price leads the evidence: RS versus the benchmark is -2%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
39Hexaware Technologies LtdHEXT 48.2/100Mixed-negative evidence94% evidence TURNING 14.5/35 Revenue 13% · PAT 1.2% · OPM change 4 pp 100% evidence 17.7/25 ROCE 30.1% · OPM 16% 100% evidence 10.5/20 P/E 24.4× · PEG 0.81 100% evidence 5.5/20 RS sector -21.4% · RS bench -9.9% · 1Y -18.7%7 of 10 weeks ahead 70% evidence
Exact sum: 14.5 + 17.7 + 10.5 + 5.5 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
40Sonata Software LtdSONATSOFTW 47.2/100Mixed-negative evidence97% evidence FADING 9.6/35 Revenue 4% · PAT 7.9% · OPM change 0 pp 95% evidence 13.6/25 ROCE 30.7% · OPM 5% 95% evidence 13.0/20 P/E 17.6× · PEG 0.81 100% evidence 11.0/20 RS sector -4.7% · RS bench -0.9% · 1Y -12.8%7 of 12 weeks ahead 100% evidence
Exact sum: 9.6 + 13.6 + 13 + 11 = 47.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
41Zensar Technologies LtdZENSARTECH 46.7/100Mixed-negative evidence100% evidence ASLEEP 16.0/35 Revenue 8% · PAT 15.3% · OPM change 0 pp 100% evidence 13.8/25 ROCE 22.8% · OPM 15% 100% evidence 13.3/20 P/E 14.3× · PEG 1.11 100% evidence 3.6/20 RS sector -26.3% · RS bench -23.3% · 1Y -37%0 of 12 weeks ahead 100% evidence
Exact sum: 16 + 13.8 + 13.3 + 3.6 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
42Unicommerce eSolutions LtdUNIECOM 46.6/100Mixed-negative evidence70% evidence ASLEEP 15.1/35 Revenue 51.6% · PAT 16.1% · OPM change -4.8 pp 83% evidence 17.1/25 ROCE 21.1% · OPM 13.4% 95% evidence 9.1/20 P/E 46.3× · PEG — 15% evidence 5.3/20 RS sector -14.5% · RS bench -24.9% · 1Y -29.2%0 of 10 weeks ahead 70% evidence
Exact sum: 15.1 + 17.1 + 9.1 + 5.3 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
43XT Global Infotech LtdXTGLOBAL 46.6/100Mixed-negative evidence61% evidence 18.8/35 Revenue 85.4% · PAT 29.4% · OPM change -6.6 pp 53% evidence 9.3/25 ROCE 7.5% · OPM 9.5% 71% evidence 9.5/20 P/E 40.8× · PEG — 50% evidence 9.0/20 RS sector -1.1% · RS bench -12.7% · 1Y -16.6%2 of 12 weeks ahead to 2026-03-29 70% evidence
Exact sum: 18.8 + 9.3 + 9.5 + 9 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
44Excelsoft Technologies LtdEXCELSOFT 44.9/100Mixed-negative evidence60% evidence ASLEEP 12.5/35 Revenue 26.8% · PAT 4.2% · OPM change -1.8 pp 95% evidence 12.2/25 ROCE 13.6% · OPM 16.3% 95% evidence 10.2/20 P/E 19.3× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence
Exact sum: 12.5 + 12.2 + 10.2 + 10 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
45Mindteck (India) LtdMINDTECK 44.3/100Mixed-negative evidence77% evidence ASLEEP 14.8/35 Revenue -4% · PAT 10.3% · OPM change 2 pp 83% evidence 10.9/25 ROCE 15.1% · OPM 10% 95% evidence 11.7/20 P/E 18× · PEG — 50% evidence 6.9/20 RS sector -10.1% · RS bench -11.7% · 1Y -5.7%3 of 10 weeks ahead 70% evidence
Exact sum: 14.8 + 10.9 + 11.7 + 6.9 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
46Magellanic Cloud LtdMCLOUD 44.3/100Mixed-negative evidence77% evidence FADING 13.3/35 Revenue 17.1% · PAT 11.7% · OPM change -3 pp 83% evidence 15.6/25 ROCE 19.8% · OPM 26% 95% evidence 11.9/20 P/E 15.1× · PEG — 50% evidence 3.5/20 RS sector -54.5% · RS bench -25.6% · 1Y -64.6%5 of 11 weeks ahead 70% evidence
Exact sum: 13.3 + 15.6 + 11.9 + 3.5 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
47Allied Digital Services LtdADSL 40.6/100Mixed-negative evidence74% evidence ASLEEP 19.4/35 Revenue 19.9% · PAT 25.8% · OPM change 0 pp 95% evidence 6.4/25 ROCE 7.3% · OPM 9% 95% evidence 10.5/20 P/E 16.7× · PEG — 15% evidence 4.3/20 RS sector -29.8% · RS bench -20% · 1Y -27.4%4 of 10 weeks ahead 70% evidence
Exact sum: 19.4 + 6.4 + 10.5 + 4.3 = 40.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
48Innovana Thinklabs LtdINNOVANA 38.9/100Mixed-negative evidence77% evidence ASLEEP 10.2/35 Revenue 27.9% · PAT -18.2% · OPM change -46.5 pp 83% evidence 10.2/25 ROCE 16.4% · OPM 9.7% 95% evidence 9.7/20 P/E 17.9× · PEG — 50% evidence 8.8/20 RS sector -0.4% · RS bench -21.6% · 1Y -34.2%0 of 10 weeks ahead 70% evidence
Exact sum: 10.2 + 10.2 + 9.7 + 8.8 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4963 Moons Technologies Ltd63MOONS 38.4/100Mixed-negative evidence62% evidence BREAKING OUT 16.7/35 Revenue 100% · PAT -17% · OPM change 397 pp 83% evidence 3.4/25 ROCE -3.7% · OPM -57% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 8.3/20 RS sector -22.4% · RS bench 15.5% · 1Y -13.3%8 of 11 weeks ahead 70% evidence
Exact sum: 16.7 + 3.4 + 10 + 8.3 = 38.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
50Kellton Tech Solutions LtdKELLTONTEC 36.8/100Mixed-negative evidence81% evidence ASLEEP 10.4/35 Revenue 9.5% · PAT 9.6% · OPM change -1 pp 95% evidence 9.8/25 ROCE 15% · OPM 11% 95% evidence 11.5/20 P/E 8.2× · PEG — 50% evidence 5.1/20 RS sector -18.8% · RS bench -25.4% · 1Y -49.8%0 of 10 weeks ahead 70% evidence
Exact sum: 10.4 + 9.8 + 11.5 + 5.1 = 36.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
51Aurionpro Solutions LtdAURIONPRO 36.5/100Mixed-negative evidence93% evidence ASLEEP 13.6/35 Revenue 14.8% · PAT 5.1% · OPM change -3 pp 100% evidence 10.8/25 ROCE 16.3% · OPM 17% 100% evidence 10.0/20 P/E 19.2× · PEG 1.39 65% evidence 2.1/20 RS sector -31% · RS bench -28.2% · 1Y -46.6%2 of 12 weeks ahead 100% evidence
Exact sum: 13.6 + 10.8 + 10 + 2.1 = 36.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
52Moschip Technologies LtdMOSCHIP 29.8/100Adverse evidence87% evidence ASLEEP 8.0/35 Revenue 8.4% · PAT -33.6% · OPM change -3.9 pp 100% evidence 7.0/25 ROCE 11% · OPM 8.2% 100% evidence 3.6/20 P/E 126× · PEG 5.04 65% evidence 11.2/20 RS sector 1.9% · RS bench -4.1% · 1Y 22.9%8 of 10 weeks ahead 70% evidence
Exact sum: 8 + 7 + 3.6 + 11.2 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
53Quick Heal Technologies LtdQUICKHEAL 19.0/100Adverse evidence69% evidence ASLEEP 6.2/35 Revenue -6.6% · PAT -80% · OPM change -22.1 pp 71% evidence 1.7/25 ROCE -4.7% · OPM -39% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 1.1/20 RS sector -35.1% · RS bench -33% · 1Y -50.2%7 of 12 weeks ahead 100% evidence
Exact sum: 6.2 + 1.7 + 10 + 1.1 = 19 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
54Covance Softsol Ltd544361 67.1/100Thin evidence · provisional49% evidence 25.8/35 Revenue 43.5% · PAT 100% · OPM change 19.7 pp 62% evidence 17.9/25 ROCE 31.4% · OPM 23.1% 76% evidence 11.2/20 P/E 12.9× · PEG — 15% evidence 12.2/20 RS sector — · RS bench 48.4% · 1Y — 25% evidence
Exact sum: 25.8 + 17.9 + 11.2 + 12.2 = 67.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
55Meta Infotech LtdMETA 54.4/100Thin evidence · provisional21% evidence 17.0/35 Revenue — · PAT — · OPM change -2 pp 10% evidence 16.3/25 ROCE 51.1% · OPM 8% 57% evidence 11.1/20 P/E 13× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y -49.5%0 of 12 weeks ahead to 2026-03-08 0% evidence
Exact sum: 17 + 16.3 + 11.1 + 10 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
56Exato Technologies Ltd544626 52.7/100Thin evidence · provisional33% evidence 17.0/35 Revenue — · PAT — · OPM change -3.9 pp 32% evidence 16.2/25 ROCE 26.8% · OPM 10.4% 76% evidence 9.5/20 P/E 39.1× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence
Exact sum: 17 + 16.2 + 9.5 + 10 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
57Kody Technolab LtdKODYTECH 52.6/100Thin evidence · provisional48% evidence TURNING 15.2/35 Revenue — · PAT — · OPM change -5 pp 19% evidence 13.0/25 ROCE 16.8% · OPM 29% 95% evidence 8.7/20 P/E 116× · PEG — 15% evidence 15.7/20 RS sector 10.3% · RS bench 56.2% · 1Y 76.9%7 of 10 weeks ahead 70% evidence
Exact sum: 15.2 + 13 + 8.7 + 15.7 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
58Unified Data- Tech Solutions LtdUNIFIED 52.6/100Thin evidence · provisional22% evidence 15.8/35 Revenue — · PAT — · OPM change -8 pp 15% evidence 16.9/25 ROCE 47.9% · OPM 13% 57% evidence 9.9/20 P/E 23.2× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y 7.9%0 of 12 weeks ahead to 2026-03-08 0% evidence
Exact sum: 15.8 + 16.9 + 9.9 + 10 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
59Trident Techlabs LtdTECHLABS 46.5/100Thin evidence · provisional40% evidence 16.1/35 Revenue — · PAT — · OPM change -2 pp 15% evidence 16.3/25 ROCE 26.7% · OPM 27% 71% evidence 10.9/20 P/E 14.9× · PEG — 15% evidence 3.2/20 RS sector -50.3% · RS bench -56.5% · 1Y -64%0 of 12 weeks ahead to 2026-03-29 70% evidence
Exact sum: 16.1 + 16.3 + 10.9 + 3.2 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
60Danlaw Technologies India Ltdthis page532329 44.9/100Thin evidence · provisional32% evidence 16.3/35 Revenue 10.9% · PAT 14% · OPM change 1.1 pp 27% evidence 7.7/25 ROCE 8.2% · OPM 8.9% 57% evidence 8.7/20 P/E 115× · PEG — 15% evidence 12.2/20 RS sector — · RS bench 44% · 1Y — 25% evidence
Exact sum: 16.3 + 7.7 + 8.7 + 12.2 = 44.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
61ERP Soft Systems Ltd530909 44.7/100Thin evidence · provisional41% evidence 20.2/35 Revenue 19.1% · PAT 100% · OPM change -1.1 pp 53% evidence 8.0/25 ROCE 1.6% · OPM 1.7% 57% evidence 8.9/20 P/E 74.9× · PEG — 15% evidence 7.6/20 RS sector — · RS bench -47.6% · 1Y -54%0 of 12 weeks ahead to 2026-03-29 25% evidence
Exact sum: 20.2 + 8 + 8.9 + 7.6 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
62Veefin Solutions LtdVEEFIN 43.3/100Thin evidence · provisional33% evidence 17.0/35 Revenue — · PAT — · OPM change -12.4 pp 5% evidence 10.4/25 ROCE 6.8% · OPM 20% 57% evidence 9.3/20 P/E 40.5× · PEG — 15% evidence 6.6/20 RS sector -7.2% · RS bench -18.7% · 1Y -28.3%0 of 12 weeks ahead to 2026-03-08 70% evidence
Exact sum: 17 + 10.4 + 9.3 + 6.6 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
63IDream Film Infrastructure Company Ltd504375 41.0/100Thin evidence · provisional30% evidence TURNING 13.5/35 Revenue — · PAT 0% · OPM change — 29% evidence 5.0/25 ROCE -9.2% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 12.5/20 RS sector — · RS bench 132.9% · 1Y —5 of 5 weeks ahead 25% evidence
Exact sum: 13.5 + 5 + 10 + 12.5 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
64Orient Technologies LtdORIENTTECH 33.5/100Thin evidence · provisional45% evidence ASLEEP 15.5/35 Revenue — · PAT — · OPM change -5 pp 13% evidence 2.3/25 ROCE 8.4% · OPM 2.4% 95% evidence 9.0/20 P/E 47.3× · PEG — 15% evidence 6.7/20 RS sector -7.1% · RS bench -17.7% · 1Y -8.6%0 of 10 weeks ahead 70% evidence
Exact sum: 15.5 + 2.3 + 9 + 6.7 = 33.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is Danlaw Technologies India Ltd's share price today?

Danlaw Technologies India Ltd trades at ₹1,198. The company is valued at ₹584 Cr. The stock sits at 100% of its 52-week range of ₹746–₹1,198, +36.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 8 weeks in. — as of 7 August 2026.

What were Danlaw Technologies India Ltd's latest quarterly results?

Danlaw Technologies India Ltd reported revenue of ₹38.0 Cr and net profit of ₹1.2 Cr for the Sep 22 quarter. Revenue rose 24.5% and profit fell 30.7% year on year. Earnings per share were ₹2.99. The operating margin was 8.9%, 1.0 pp higher than a year earlier. — as of 7 August 2026.

What is Danlaw Technologies India Ltd's revenue?

Danlaw Technologies India Ltd reported revenue of ₹38.0 Cr in the Sep 22 quarter, +24.5% year on year. For the full FY22 fiscal year, revenue was ₹122 Cr (+23.2%). Over the last 10 years revenue compounded at 29.8% a year. — as of 7 August 2026.

What is Danlaw Technologies India Ltd's profit?

Danlaw Technologies India Ltd earned ₹1.2 Cr of net profit in the Sep 22 quarter, −30.7% year on year. Full-year FY22 profit was ₹4.0 Cr. The operating margin ran 8.9% in the latest quarter. — as of 7 August 2026.

What is Danlaw Technologies India Ltd's market cap?

Danlaw Technologies India Ltd's market capitalisation is ₹584 Cr at a share price of ₹1,198. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 7 August 2026.

What is Danlaw Technologies India Ltd's P/E ratio?

Danlaw Technologies India Ltd trades at a P/E of 115.0×, at the 79th percentile of its own 10-year range, against a long-run median of 56.8×. This is a comparison with the stock's own history, not a value call — as of 7 August 2026.

Does Danlaw Technologies India Ltd pay a dividend?

No — Danlaw Technologies India Ltd has recorded a dividend payout of 0% of profit in each of its last 12 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 7 August 2026.

Is Danlaw Technologies India Ltd overvalued?

On its own history, Danlaw Technologies India Ltd looks expensive against its own history: its P/E of 115.0× sits at the 79th percentile of its 10-year range (long-run median 56.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 7 August 2026.

Is Danlaw Technologies India Ltd growing?

Yes — Danlaw Technologies India Ltd is growing: latest-quarter revenue +24.5% year on year, profit −30.7%, and the margin +1.0 pp at 8.9%. The earnings engine currently reads: improving — as of 7 August 2026.

How is Danlaw Technologies India Ltd performing?

Danlaw Technologies India Ltd is in a confirmed uptrend, 8 weeks in. Its latest quarter's revenue rose 24.5% and profit fell 30.7% year on year. This describes what the data did, not a rating. — as of 7 August 2026.

Is Danlaw Technologies India Ltd in an uptrend?

Yes — the price is in a confirmed uptrend (week 8 of stage 2), trading +36.5% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 7 August 2026.

Will Danlaw Technologies India Ltd's share price go up?

This page publishes no price forecast for Danlaw Technologies India Ltd. What it measures instead: the share price is ₹1,198, the price is in a confirmed uptrend 8 weeks in. Its P/E of 115.0× sits at the 79th percentile of its own 10-year range. — as of 7 August 2026.

Who owns Danlaw Technologies India Ltd?

Promoters hold 61.9% of Danlaw Technologies India Ltd, foreign institutions 0.0%, domestic institutions 0.0% and the public 37.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 7 August 2026.

Does Danlaw Technologies India Ltd have too much debt?

It is moderate — Danlaw Technologies India Ltd's debt-to-equity is 0.52, and operating profit covers the interest bill 3×. FY22 borrowings were ₹12.0 Cr against equity of ₹23.0 Cr. Read the returns on this page with that leverage in mind — as of 7 August 2026.

What is Danlaw Technologies India Ltd's capex?

Danlaw Technologies India Ltd spent ₹29.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY22 alone that was ₹5.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 7 August 2026.

What is Danlaw Technologies India Ltd's cash flow?

Danlaw Technologies India Ltd generated ₹6.0 Cr of operating cash flow in FY22 and ₹1.0 Cr of free cash flow after ₹5.0 Cr of capital spending. Reported profit that year was ₹4.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 7 August 2026.

Is Danlaw Technologies India Ltd's profit real cash?

Not fully — over the last 3 fiscal years, 29% of Danlaw Technologies India Ltd's reported profit arrived as operating cash. In FY22, operating cash was ₹6.0 Cr against reported profit of ₹4.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 7 August 2026.

Where is Danlaw Technologies India Ltd in its business cycle?

Danlaw Technologies India Ltd's FY22 operating margin was 5.0%, against a 12-year band of −8.0%–18.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 8.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 7 August 2026.

What could break the Danlaw Technologies India Ltd story?

The sharpest disagreement: profits are rising, but only 29% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 7 August 2026.

Is Danlaw Technologies India Ltd a stock worth studying right now?

This is not investment advice. The machine read: Danlaw Technologies India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 7 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI